MTOR and neoplasm: A strong enrichment of the CD4+ Th1 (IFNGhi, TNFhi, TBX21hi, GZMBhi) subpopulation was observed exclusively in the PI3K/mTOR+PD‐1i‐treated tumours (Figure 3F) and DGE analysis revealed this population upregulates the expression of immune response promoting factors (IFNG, TNF, CSF2, TNFSF10 (TRAIL), TNFSF14 (LIGHT), CCL3) (Figure 3G).